This study encourages attempts to examine to what extent targeting DSCAM-AS1, e.g., by antisense-oligonucleotide (ASO) approaches, might be efficient in the therapy of endometrial cancer [72]. The gene discussed is DSCAM; the disease is endometrial cancer.